fingolimod hydrochloride has been researched along with Diabetic Glomerulosclerosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awad, AS; Bolton, WK; Huang, L; Khutsishvili, K; Lynch, KR; Okusa, MD; Rouse, MD | 1 |
1 other study(ies) available for fingolimod hydrochloride and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fingolimod Hydrochloride; Kidney; Lymphocytes; Mice; Mice, Inbred C57BL; Oxadiazoles; Phosphotransferases (Alcohol Group Acceptor); Podocytes; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Thiophenes; Tumor Necrosis Factor-alpha | 2011 |